6340 Sequence Drive
251 articles with DexCom
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
Data could support future efforts to make real-time CGM a standard tool for glycemic assessment in the hospital setting Real-world evidence will be gathered from healthcare providers and hospital institutions using real-time CGM with hospitalized patients SAN DIEGO--( BUSINESS WIRE )-- DexCom , Inc. ( NASDAQ:DXCM ), the leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today the first ever
DexCom, Inc. announced that management will present an update on Dexcom
Health Canada Authorizes Interim Use of Dexcom G6 CGM by Pregnant Women in Response to the COVID-19 Pandemic
Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring system by pregnant women with Type 1, Type 2, or gestational diabetes.
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to review the company's second quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor rela
KORE , the independent global IoT leader, today announced an ongoing partnership with Dexcom, Inc., the world leader in continuous glucose monitoring (CGM), to rapidly deliver an innovative remote patient monitoring solution to assist care providers during the COVID-19 global pandemic.
DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference
DexCom, Inc. announced the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
DexCom, Inc. announced that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior Notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
DexCom, Inc. announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. has been changed and will be held as a hybrid meeting that stockholders can attend either in person or virtually via live webcast, though the Company strongly encourages stockholders to participate virtually.
Health Canada Temporarily Authorizes Dexcom G6 CGM for Use in Hospitals to Monitor Critically Ill Patients During COVID-19 Pandemic
Health Canada recently announced the Dexcom G6 Continuous Glucose Monitoring system has been temporarily authorized for expanded use in hospitals, in an effort to help remotely monitor those who are critically ill during the COVID-19 pandemic.
DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2020.
Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic
DexCom , Inc. ( NASDAQ:DXCM ), the leader in continuous glucose monitoring (CGM) systems for people with diabetes, announced today a new patient assistance program to aid current U.S. customers who have lost insurance due to the COVID-19 pandemic. When the program launches for current customers who meet eligibility requirements, Dexcom will: Enroll eligible customers in the program during the COVID-19 pandemic
Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, April 28, 2020.
Welldoc Announces Collaboration with Dexcom to Enhance the Value of BlueStar® with the Dexcom G6® CGM System
Welldoc, announced today a collaboration with Dexcom, the global leader in continuous glucose monitoring (CGM) systems for people with diabetes.
Feb. 24, 2020 21:15 UTC Dexcom to Present at Cowen 40 th Annual Healthcare Conference SAN DIEGO--( BUSINESS WIRE )-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference: Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Cowen 40 th Annual Healthcare Conference in Boston, MA, on Monday, March 2, 2020, at 3:30 PM
Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System
Feb. 19, 2020 12:00 UTC First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required Integration with the next generation Dexcom G7 CGM system, once available SAN DIEGO & ACTON, Mass.--( BUSINESS WIRE )-- DexCom , Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreem
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc., the leader in continuous glucose monitoring, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018.
Livongo and Dexcom Partner to Integrate Dexcom’s G6 Continuous Glucose Monitoring System into Livongo’s Applied Health Signals Platform
Dexcom CGM to become a core part of Livongo’s solution for delivering personalized health insights and improved clinical outcomes to people with Diabetes
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare Conference on January 13, 2020.